Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo.

Schlüter A, Aksan B, Fioravanti R, Valente S, Mai A, Mauceri D.

Mol Neurobiol. 2019 Jun 3. doi: 10.1007/s12035-019-01658-x. [Epub ahead of print]

PMID:
31161423
2.

Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells.

Zwergel C, Schnekenburger M, Sarno F, Battistelli C, Manara MC, Stazi G, Mazzone R, Fioravanti R, Gros C, Ausseil F, Florean C, Nebbioso A, Strippoli R, Ushijima T, Scotlandi K, Tripodi M, Arimondo PB, Altucci L, Diederich M, Mai A, Valente S.

Clin Epigenetics. 2019 May 6;11(1):68. doi: 10.1186/s13148-019-0663-8.

3.

Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer.

Stazi G, Fioravanti R, Mai A, Mattevi A, Valente S.

Curr Opin Chem Biol. 2019 Jun;50:89-100. doi: 10.1016/j.cbpa.2019.03.002. Epub 2019 Apr 12. Review.

PMID:
30986654
4.

Statins and Histone Deacetylase Inhibitors Affect Lamin A/C - Histone Deacetylase 2 Interaction in Human Cells.

Mattioli E, Andrenacci D, Mai A, Valente S, Robijns J, De Vos WH, Capanni C, Lattanzi G.

Front Cell Dev Biol. 2019 Jan 31;7:6. doi: 10.3389/fcell.2019.00006. eCollection 2019.

5.

The medial coracoclavicular ligament: anatomy, biomechanics,and clinical relevance-a research study.

Moya D, Poitevin LA, Postan D, Azulay GA, Valente S, Giacomelli F, Mamone LA.

JSES Open Access. 2018 Sep 22;2(4):183-189. doi: 10.1016/j.jses.2018.07.001. eCollection 2018 Dec.

6.

Development of alkyl glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-mesenchymal transition in cancer cells.

Stazi G, Battistelli C, Piano V, Mazzone R, Marrocco B, Marchese S, Louie SM, Zwergel C, Antonini L, Patsilinakos A, Ragno R, Viviano M, Sbardella G, Ciogli A, Fabrizi G, Cirilli R, Strippoli R, Marchetti A, Tripodi M, Nomura DK, Mattevi A, Mai A, Valente S.

Eur J Med Chem. 2019 Feb 1;163:722-735. doi: 10.1016/j.ejmech.2018.11.050. Epub 2018 Nov 28.

PMID:
30576903
7.

Application of Small Epigenetic Modulators in Pediatric Medulloblastoma.

Zwergel C, Romanelli A, Stazi G, Besharat ZM, Catanzaro G, Tafani M, Valente S, Mai A.

Front Pediatr. 2018 Dec 3;6:370. doi: 10.3389/fped.2018.00370. eCollection 2018. Review.

8.

Identification of novel quinazoline derivatives as potent antiplasmodial agents.

Bouchut A, Rotili D, Pierrot C, Valente S, Lafitte S, Schultz J, Hoglund U, Mazzone R, Lucidi A, Fabrizi G, Pechalrieu D, Arimondo PB, Skinner-Adams TS, Chua MJ, Andrews KT, Mai A, Khalife J.

Eur J Med Chem. 2019 Jan 1;161:277-291. doi: 10.1016/j.ejmech.2018.10.041. Epub 2018 Oct 17.

PMID:
30366254
9.

Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.

Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A.

Chem Rec. 2018 Dec;18(12):1818-1832. doi: 10.1002/tcr.201800091. Epub 2018 Oct 19. Review.

PMID:
30338896
10.

Altered modulation of lamin A/C-HDAC2 interaction and p21 expression during oxidative stress response in HGPS.

Mattioli E, Andrenacci D, Garofalo C, Prencipe S, Scotlandi K, Remondini D, Gentilini D, Di Blasio AM, Valente S, Scarano E, Cicchilitti L, Piaggio G, Mai A, Lattanzi G.

Aging Cell. 2018 Oct;17(5):e12824. doi: 10.1111/acel.12824. Epub 2018 Aug 15. Erratum in: Aging Cell. 2018 Dec;17(6):e12885.

11.

Correction to 'Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells'.

Mellini P, Marrocco B, Borovika D, Polletta L, Carnevale I, Saladini S, Stazi G, Zwergel C, Trapencieris P, Ferretti E, Tafani M, Valente S, Mai A.

Philos Trans R Soc Lond B Biol Sci. 2018 Sep 19;373(1755). pii: 20180305. doi: 10.1098/rstb.2018.0305. No abstract available.

12.

A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy.

Manara MC, Valente S, Cristalli C, Nicoletti G, Landuzzi L, Zwergel C, Mazzone R, Stazi G, Arimondo PB, Pasello M, Guerzoni C, Picci P, Nanni P, Lollini PL, Mai A, Scotlandi K.

Mol Cancer Ther. 2018 Sep;17(9):1881-1892. doi: 10.1158/1535-7163.MCT-17-0818. Epub 2018 Jun 29.

PMID:
29959201
13.

Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia.

Singh AA, Petraglia F, Nebbioso A, Yi G, Conte M, Valente S, Mandoli A, Scisciola L, Lindeboom R, Kerstens H, Janssen-Megens EM, Pourfarzad F, Habibi E, Berentsen K, Kim B, Logie C, Heath S, Wierenga ATJ, Clarke L, Flicek P, Jansen JH, Kuijpers T, Yaspo ML, Valle VD, Bernard O, Gut I, Vellenga E, Stunnenberg HG, Mai A, Altucci L, Martens JHA.

Oncotarget. 2018 May 22;9(39):25647-25660. doi: 10.18632/oncotarget.25429. eCollection 2018 May 22.

14.

Combined HAT/EZH2 modulation leads to cancer-selective cell death.

Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-Megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L.

Oncotarget. 2018 May 22;9(39):25630-25646. doi: 10.18632/oncotarget.25428. eCollection 2018 May 22.

15.

HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal.

Rossi L, Battistelli C, de Turris V, Noce V, Zwergel C, Valente S, Moioli A, Manzione A, Palladino M, Bordoni V, Domenici A, Menè P, Mai A, Tripodi M, Strippoli R.

Sci Rep. 2018 May 31;8(1):8492. doi: 10.1038/s41598-018-26319-2.

16.

Trends of LSD1 inhibitors in viral infections.

Zwergel C, Stazi G, Mai A, Valente S.

Future Med Chem. 2018 May 1;10(10):1133-1136. doi: 10.4155/fmc-2018-0065. Epub 2018 May 22. No abstract available.

17.

Pyrazole-based inhibitors of enhancer of zeste homologue 2 induce apoptosis and autophagy in cancer cells.

Mellini P, Marrocco B, Borovika D, Polletta L, Carnevale I, Saladini S, Stazi G, Zwergel C, Trapencieris P, Ferretti E, Tafani M, Valente S, Mai A.

Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748). pii: 20170150. doi: 10.1098/rstb.2017.0150. Erratum in: Philos Trans R Soc Lond B Biol Sci. 2018 Sep 19;373(1755):.

18.

Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice.

Buonvicino D, Felici R, Ranieri G, Caramelli R, Lapucci A, Cavone L, Muzzi M, Di Pietro L, Bernardini C, Zwergel C, Valente S, Mai A, Chiarugi A.

Neuroscience. 2018 May 21;379:228-238. doi: 10.1016/j.neuroscience.2018.03.022. Epub 2018 Mar 26.

PMID:
29588251
19.

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.

Kalin JH, Wu M, Gomez AV, Song Y, Das J, Hayward D, Adejola N, Wu M, Panova I, Chung HJ, Kim E, Roberts HJ, Roberts JM, Prusevich P, Jeliazkov JR, Roy Burman SS, Fairall L, Milano C, Eroglu A, Proby CM, Dinkova-Kostova AT, Hancock WW, Gray JJ, Bradner JE, Valente S, Mai A, Anders NM, Rudek MA, Hu Y, Ryu B, Schwabe JWR, Mattevi A, Alani RM, Cole PA.

Nat Commun. 2018 Jan 4;9(1):53. doi: 10.1038/s41467-017-02242-4.

20.

The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.

Miele E, Valente S, Alfano V, Silvano M, Mellini P, Borovika D, Marrocco B, Po A, Besharat ZM, Catanzaro G, Battaglia G, Abballe L, Zwergel C, Stazi G, Milite C, Castellano S, Tafani M, Trapencieris P, Mai A, Ferretti E.

Oncotarget. 2017 Aug 2;8(40):68557-68570. doi: 10.18632/oncotarget.19782. eCollection 2017 Sep 15.

Supplemental Content

Loading ...
Support Center